Investigative radiology
-
Investigative radiology · Jan 1993
The night stalker effect: quality improvements with a dedicated night-call rotation.
The authors assessed whether a non-sleep-deprived, second-year diagnostic radiology resident assigned to an after-hours "night stalker" emergency radiology (ER) rotation in an urban university hospital has a measurable impact on the number and clinical significance of "missed" radiologic findings. ⋯ A dedicated night-shift ER coverage of a busy urban ED improves quality, appropriateness, and timeliness of patient care.
-
Investigative radiology · Jan 1993
Computed tomography and histologic results in the early stages of endotoxin-injured pig lungs as a model for adult respiratory distress syndrome.
To determine early radiographic changes in diffuse alveolar injury, the authors correlated computed tomography (CT) and histopathology in pigs with recurrent endotoxinemia. ⋯ CT clearly depicts changes in endotoxin-injured pig lungs in an early clinical state, which are similar to changes associated with ARDS on histologic examination.
-
Investigative radiology · Aug 1992
Comparative StudyGadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) is a new hepatobiliary magnetic resonance imaging (MRI) contrast agent with a dual elimination: 70% via the liver and bile and 30% via the kidney in normal rats. The abdominal enhancement patterns of this new compound and the uptake mechanism by the liver were studied in rats using tissue relaxometry and MRI. ⋯ Data indicate that transport of Gd-EOB-DTPA through the liver into bile is driven by the organic anion transporter. The relation between enhancement of liver and kidney may be diagnostically useful to indirectly evaluate liver excretory function. Yet, persistent enhancement of liver, even in the presence of severe hyperbilirubinemia, should be sufficient to identify focal mass lesions.
-
Investigative radiology · Aug 1992
Multicenter Study Clinical TrialPhase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
The safety and efficacy of a new, low-osmolal magnetic resonance imaging contrast medium, gadoteridol injection, were evaluated in a phase II, open-label study at doses ranging from 0.05 to 0.30 mmol/kg. ⋯ Overall, enhanced images provided more diagnostic information and facilitated detection of more lesions than precontrast images. Gadoteridol injection at doses up to 0.3 mmol/kg is a safe and effective magnetic resonance imaging contrast agent for use in patients with intracranial tumors.